Prelude nabs $60M series B, gains biopharma veteran CMO by Ben Adams Wednesday, June 12, 2019 Prelude Therapeutics has completed a $60 million series B round as it looks to push its cancer work into the clinic.
Advaxis suffers another blow as FDA puts phase 3 on partial hold by Nick Paul Taylor Thursday, January 24, 2019 Advaxis suffered the latest in a string of setbacks after the FDA requested chemistry, manufacturing and controls information.
Advaxis cuts staff, seeks partner for troubled cancer vaccine by Phil Taylor Friday, June 8, 2018 Almost a quarter of Advaxis' workforce is facing the chop as it scales back trials of its lead cancer immunotherapy, currently on clinical hold.
Chutes & Ladders—Sanofi hires ex-Roche executive as R&D chief by Conor Hale Friday, April 27, 2018 Sanofi hires ex-Roche executive as R&D chief, Advaxis names former Rosetta Genomics chief as CEO, and Urovant steals Allergan’s key urology VP.
Kenneth Berlin to head up Advaxis after executive shuffle by Amirah Al Idrus Monday, April 23, 2018 Kenneth Berlin and Andres Gutierrez will join Advaxis as CEO and chief medical officer.
FDA puts clinical hold on Advaxis, AstraZeneca combination trial by Nick Paul Taylor Tuesday, March 13, 2018 Regulatory officials took the action upon learning a cervical cancer patient developed respiratory failure and died after receiving the combination.
Chutes & Ladders—AstraZeneca chief Soriot may abscond to Teva by Angus Liu Thursday, July 13, 2017 AZ CEO Pascal Soriot was said to be joining Teva as CEO, GSK poached Pfizer's medicinal sciences head, and Advaxis CEO O'Connor abruptly resigned.
O’Connor resigns as CEO of Advaxis with immediate effect by Nick Paul Taylor Friday, July 7, 2017 Daniel O’Connor has resigned as CEO of Advaxis, which has put CBO Tony Lombardo in charge while it searches for a permanent successor.
Chutes & Ladders—Embattled Juno taps new R&D head by Angus Liu Thursday, April 20, 2017 Juno tapped Genentech alum Sunil Agarwal as new R&D chief, Merrimack promoted Onivyde scientist Daryl Drummond as head of research, and Mitch Gold leads the newly merged Alpine.
Advaxis gets OK to test Amgen-partnered neoantigen cancer vaccine by Phil Taylor Monday, March 6, 2017 Advaxis and Amgen get an FDA OK to start testing their neoantigen cancer vaccine, partnered in a $540 million deal last year.
